


Claim Amendments

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-10. (Canceled)

Claim 11. (Currently Amended) A piperazine benzothiazole compound having formula I



as well as its tautomers, its geometrical isomers, its optically active forms as an enantiomer, a diastereomer and as a racemate, as well as pharmaceutically acceptable salts thereof, wherein

R is selected from the group comprising or consisting of hydrogen, C₁-C₆-alkyl, C₁-C₆-alkyl aryl, heteroaryl, C₁-C₆-alkyl heteroaryl, C₂-C₆-alkenyl, C₂-C₆-alkenyl aryl, C₂-C₆-alkenyl heteroaryl, C₂-C₆-alkynyl, C₂-C₆-alkynyl aryl, C₂-C₆-alkynyl heteroaryl, C₃-C₈-cycloalkyl, heterocycloalkyl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl, C₁-C₆-alkyl carboxy, acyl, C₁-C₆-alkyl acyl, acyloxy, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl alkoxy, alkoxycarbonyl, C₁-C₆-alkyl alkoxycarbonyl, aminocarbonyl, C₁-C₆-alkyl aminocarbonyl, acylamino, C₁-C₆-alkyl acylamino, ureido, C₁-C₆-alkyl ureido, amino, C₁-C₆-alkyl amino, sulfonyloxy, C₁-C₆-alkyl sulfonyloxy, sulfonyl, C₁-C₆-alkyl sulfonyl, sulfinyl, C₁-C₆-alkyl sulfinyl, sulfanyl, C₁-C₆-alkyl sulfanyl, sulfonylamino, and C₁-C₆-alkyl sulfonylamino;

R^1 is selected from the group comprising or consisting of H, halogen, cyano, nitro, amino, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -alkyl-aryl, aryl or heteroaryl, C_1 - C_6 -alkyl-heteroaryl, $-C(O)-OR^2$, $-C(O)-R^2$, $-C(O)-NR^2R^{2'}$, and $-(SO_2)R^2$, with

R^2 and $R^{2'}$ being independently selected from the group comprising or consisting of hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl, heteroaryl, C_1 - C_6 -alkyl aryl, C_1 - C_6 -alkyl heteroaryl and combinations mixtures thereof; and

n is an integer from 0 to 3.

Claim 12. (Previously Presented) The piperazine benzothiazole compound according to claim 11, wherein R^1 is hydrogen.

Claim 13. (Previously Presented) The piperazine benzothiazole compound according to claim 11, wherein R is selected from the group consisting of hydrogen, C_1 - C_3 alkyl, aminocarbonyl, C_1 - C_6 -alkyl alkoxycarbonyl, C_1 - C_6 -alkyl alkoxy, C_1 - C_6 -alkyl acyloxy, alkoxycarbonyl, and C_1 - C_6 -alkyl aminocarbonyl.

Claim 14. (Previously Presented) The piperazine benzothiazole compound according to claim 13, wherein R is H, or C_1 - C_3 alkyl, in particular a methyl or an ethyl moiety, or C_1 - C_6 -alkyl alkoxy.

Claim 15. (Previously Presented) The piperazine benzothiazole compound according to claim 11, wherein n is 1.

Claim 16. (Previously Presented) The piperazine benzothiazole compound according to claim 11 selected from the group consisting of:

1,3-benzothiazol-2-yl[2-({4-[(4-methylpiperazin-1-yl)methyl]benzyl} oxy)pyrimidin-4-yl]acetonitrile,

1,3-benzothiazol-2-yl[2-({4-[(4-benzyl-piperazin-1-yl)methyl]-benzyl} oxy)pyrimidin-4-yl]acetonitrile,

1,3-benzothiazol-2-yl(2-{[4-(piperazin-1-ylmethyl)benzyl]oxy}pyrimidin-4-yl)acetonitrile,

1,3-benzothiazol-2-yl[2-({4-[(4-formylpiperazin-1-yl)methyl]benzyl} oxy)pyrimidin-4-yl]acetonitrile,

[2-({4-[(4-acetyl)piperazin-1-yl)methyl]benzyl} oxy)pyrimidin-4-yl](1,3-benzothiazol-2-yl)acetonitrile,

(3H-Benzothiazol-2-ylidene)-{2-[4-(4-[1,2,4]oxadiazol-3-ylmethyl-piperazin-1-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile,

4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-1-carboxylic acid methyl ester,

2-[4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-1-yl]-acetamide,

(2-{4-[4-(2-Amino-acetyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-(3H-benzothiazol-2-ylidene)-acetonitrile,

[4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-1-yl]-acetic acid methyl ester,

(3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-methoxy-ethyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile,

4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-1-carboxylic acid dimethylamide,

(3H-Benzothiazol-2-ylidene)-{2-[4-(4-ethyl-piperazin-1-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile, and

(3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile.

Claims 17 to 19. (Canceled)

Claim 20. (Currently Amended) A pharmaceutical composition, comprising:


a therapeutically effective amount of the piperazine benzothiazole compound according to claim 11 with a pharmaceutically acceptable carrier.

Claim 21. (Previously Presented) A method of treating ischemia, comprising:


administering a therapeutically effective amount of the pharmaceutical composition according to claim 20 to a subject in need of treatment for ischemia.

Claim 22. (Previously Presented) A process for the preparation of a piperazine benzothiazole compound claimed in claim 11, comprising:

reacting a pyrimidinylbenzothiazole compound of formula (IV)



with a piperazinyl alcohol compound of formula (V)



wherein R, R¹ and n are as defined in claim 11, thereby preparing the piperazine benzothiazole compound of claim 11.